0.96 USD
▲-0.07+0.01%
盘后 1.03 +7.29%
2026-08-03
市值
$9.45M
市盈率
—
EPS
-2.21
股息率
—
52 周区间
0.94 – 2.73
成交量
37.74K
Beta
0.22
目标价
6.25
52W 低 0.9452W 高 2.73
价格走势
公司简介
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinic...